Symbols / DRMA Stock $1.24 -1.98% Dermata Therapeutics, Inc.
DRMA (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifies, develops, and commercializes pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications in the United States. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Ratings
Current target
$1.24
Low
$4.00
High
$4.00
Mean
$4.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-21 | main | Maxim Group | Buy → Buy | $10 |
| 2025-05-21 | main | Maxim Group | Buy → Buy | $3 |
| 2024-08-21 | main | Maxim Group | Buy → Buy | $6 |
| 2023-03-23 | main | Maxim Group | — → Buy | $4 |
- Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan Wed, 22 Apr 2026 20
- Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beat - - Cổng thông tin điện tử Tỉnh Sơn La Wed, 22 Apr 2026 18
- $DRMA stock is up 16% today. Here's what we see in our data. - Quiver Quantitative Fri, 20 Mar 2026 07
- DRMA News | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill Fri, 17 Apr 2026 07
- Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today? - Stocktwits Wed, 24 Dec 2025 08
- Dermata lines up as much as $12.4M to help launch OTC acne kit - Stock Titan Wed, 24 Dec 2025 08
- Are investors bearish on Dermata (DRMA) Stock | Price at $1.25, Up 2.87% - Expert Breakout Alerts - Cổng thông tin điện tử tỉnh Lào Cai Mon, 13 Apr 2026 07
- Is Dermata (DRMA) Stock Near Resistance | Price at $1.31, Up 1.94% - Price Target - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan hu, 02 Apr 2026 07
- 3.3M Australians with acne: Dermata's new treatment patent - Stock Titan ue, 20 Jan 2026 08
- Skincare firm Dermata raises $4.1M to back new over-the-counter acne kit - Stock Titan Mon, 29 Dec 2025 08
- Dermata Therapeutics (NASDAQ: DRMA) teases OTC brand, plans 2026 acne kit launch - Stock Titan hu, 04 Dec 2025 08
- Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan Fri, 17 Apr 2026 21
- [ARS] Dermata Therapeutics, Inc. SEC Filing - Stock Titan Fri, 17 Apr 2026 07
- New Dermata marketing chief to launch Tome skincare line in 2026 - Stock Titan ue, 10 Mar 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
7.77
-37.88%
|
12.51
+55.60%
|
8.04
-16.88%
|
9.67
|
| Research And Development |
|
2.93
-64.28%
|
8.20
+101.58%
|
4.07
-27.98%
|
5.65
|
| Selling General And Administration |
|
4.84
+12.39%
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| General And Administrative Expense |
|
—
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| Other Gand A |
|
—
|
4.31
+8.49%
|
3.97
-1.28%
|
4.02
|
| Total Expenses |
|
7.77
-37.88%
|
12.51
+55.60%
|
8.04
-16.88%
|
9.67
|
| Operating Income |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Total Operating Income As Reported |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| EBITDA |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Normalized EBITDA |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Reconciled Depreciation |
|
—
|
—
|
—
|
—
|
| EBIT |
|
-7.77
+37.88%
|
-12.51
-55.60%
|
-8.04
+16.88%
|
-9.67
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Pretax Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Non Operating Interest Income Expense |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Expense Non Operating |
|
—
|
—
|
—
|
-0.06
|
| Net Interest Income |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Expense |
|
—
|
—
|
—
|
-0.06
|
| Interest Income Non Operating |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Interest Income |
|
0.22
-4.76%
|
0.23
-8.67%
|
0.25
+288.87%
|
0.06
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income From Continuing And Discontinued Operation |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income Continuous Operations |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Normalized Income |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Net Income Common Stockholders |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Diluted EPS |
|
—
|
-80.32
+79.91%
|
-399.90
+80.85%
|
-2,088.00
|
| Basic EPS |
|
—
|
-80.32
+79.91%
|
-399.90
+80.85%
|
-2,088.00
|
| Basic Average Shares |
|
—
|
0.15
+684.80%
|
0.02
+323.37%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.15
+684.80%
|
0.02
+323.37%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Preferred Stock Dividends |
|
—
|
—
|
—
|
—
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.06
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
7.86
+122.53%
|
3.53
-55.71%
|
7.98
+14.89%
|
6.94
|
| Current Assets |
|
7.86
+122.53%
|
3.53
-55.71%
|
7.98
+14.89%
|
6.94
|
| Cash Cash Equivalents And Short Term Investments |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Cash And Cash Equivalents |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Cash Financial |
|
—
|
—
|
—
|
—
|
| Receivables |
|
—
|
—
|
0.01
-33.69%
|
0.01
|
| Other Receivables |
|
—
|
—
|
—
|
0.01
|
| Accrued Interest Receivable |
|
—
|
—
|
0.01
-33.69%
|
0.01
|
| Prepaid Assets |
|
0.34
-8.18%
|
0.37
-31.12%
|
0.54
-21.73%
|
0.69
|
| Current Deferred Assets |
|
—
|
—
|
—
|
0.00
|
| Other Current Assets |
|
—
|
—
|
0.01
+24.94%
|
0.01
|
| Total Non Current Assets |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Total Liabilities Net Minority Interest |
|
1.64
-16.85%
|
1.97
+21.51%
|
1.62
+75.98%
|
0.92
|
| Current Liabilities |
|
1.64
-16.85%
|
1.97
+21.51%
|
1.62
+75.98%
|
0.92
|
| Payables And Accrued Expenses |
|
0.66
-46.74%
|
1.24
+36.82%
|
0.91
+20.59%
|
0.75
|
| Payables |
|
0.46
-42.97%
|
0.81
-6.70%
|
0.87
+74.36%
|
0.50
|
| Accounts Payable |
|
0.46
-42.97%
|
0.81
-6.70%
|
0.87
+74.36%
|
0.50
|
| Current Accrued Expenses |
|
0.20
-53.78%
|
0.43
+953.95%
|
0.04
-83.92%
|
0.26
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.98
+33.87%
|
0.73
+2.11%
|
0.72
+320.50%
|
0.17
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Common Stock Equity |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Capital Stock |
|
0.00
+964.00%
|
0.00
-3.85%
|
0.00
-66.23%
|
0.00
|
| Common Stock |
|
0.00
+964.00%
|
0.00
-3.85%
|
0.00
-66.23%
|
0.00
|
| Share Issued |
|
3.20
+1170.12%
|
0.25
+860.79%
|
0.03
+410.42%
|
0.01
|
| Ordinary Shares Number |
|
3.20
+1170.12%
|
0.25
+860.79%
|
0.03
+410.42%
|
0.01
|
| Additional Paid In Capital |
|
79.46
+18.18%
|
67.24
+12.54%
|
59.74
+15.75%
|
51.61
|
| Retained Earnings |
|
-73.23
-11.51%
|
-65.68
-23.02%
|
-53.39
-17.10%
|
-45.59
|
| Total Equity Gross Minority Interest |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Total Capitalization |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Working Capital |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Invested Capital |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Net Tangible Assets |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Tangible Book Value |
|
6.22
+298.66%
|
1.56
-75.44%
|
6.36
+5.53%
|
6.02
|
| Interest Payable |
|
—
|
—
|
—
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Cash Flow From Continuing Operating Activities |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Net Income From Continuing Operations |
|
-7.56
+38.49%
|
-12.29
-57.64%
|
-7.79
+18.90%
|
-9.61
|
| Depreciation Amortization Depletion |
|
—
|
—
|
—
|
—
|
| Depreciation |
|
—
|
—
|
—
|
—
|
| Depreciation And Amortization |
|
—
|
—
|
—
|
—
|
| Other Non Cash Items |
|
—
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.14
-78.14%
|
0.66
+25.97%
|
0.52
-43.88%
|
0.93
|
| Change In Working Capital |
|
-0.34
-173.41%
|
0.47
-45.94%
|
0.86
+662.38%
|
-0.15
|
| Change In Prepaid Assets |
|
0.03
-81.88%
|
0.17
+3.37%
|
0.16
+33.42%
|
0.12
|
| Change In Payables And Accrued Expense |
|
-0.37
-224.95%
|
0.30
-57.39%
|
0.70
+354.43%
|
-0.28
|
| Change In Accrued Expense |
|
0.01
-96.35%
|
0.41
+22.78%
|
0.33
+229.06%
|
-0.26
|
| Change In Payable |
|
-0.39
-257.62%
|
-0.11
-129.38%
|
0.37
+2091.73%
|
-0.02
|
| Change In Account Payable |
|
-0.39
-257.62%
|
-0.11
-129.38%
|
0.37
+2091.73%
|
-0.02
|
| Change In Other Current Liabilities |
|
—
|
—
|
—
|
—
|
| Financing Cash Flow |
|
12.12
+75.97%
|
6.89
-9.46%
|
7.61
+77.84%
|
4.28
|
| Cash Flow From Continuing Financing Activities |
|
12.12
+75.97%
|
6.89
-9.46%
|
7.61
+77.84%
|
4.28
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Short Term Debt Payments |
|
—
|
—
|
—
|
—
|
| Net Short Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
12.17
+76.72%
|
6.89
-9.47%
|
7.61
+77.85%
|
4.28
|
| Common Stock Payments |
|
-0.00
+55.68%
|
-0.00
-1970.00%
|
-0.00
|
0.00
|
| Repurchase Of Capital Stock |
|
-0.00
+55.68%
|
-0.00
-1970.00%
|
-0.00
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-11.90%
|
0.00
+493.05%
|
0.00
-34.84%
|
0.00
|
| Net Other Financing Charges |
|
-0.05
|
—
|
—
|
—
|
| Changes In Cash |
|
4.36
+201.96%
|
-4.28
-457.32%
|
1.20
+126.26%
|
-4.56
|
| Beginning Cash Position |
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
-42.20%
|
10.80
|
| End Cash Position |
|
7.52
+137.92%
|
3.16
-57.50%
|
7.44
+19.18%
|
6.24
|
| Free Cash Flow |
|
-7.76
+30.51%
|
-11.16
-74.18%
|
-6.41
+27.45%
|
-8.83
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Common Stock Issuance |
|
12.17
+76.70%
|
6.89
-9.46%
|
7.61
+77.85%
|
4.28
|
| Issuance Of Capital Stock |
|
12.17
+76.70%
|
6.89
-9.46%
|
7.61
+77.85%
|
4.28
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-26 View
- 8-K2026-03-26 View
- 42026-03-17 View
- 8-K2026-02-25 View
- 8-K2026-02-03 View
- 8-K2026-01-27 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42026-01-06 View
- 42025-12-29 View
- 42025-12-29 View
- 8-K2025-12-29 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|